Skip to main content

Table 1 Summary of all cases used in this study. See supplementary data for subgroup analyses

From: Quantitative patterns of motor cortex proteinopathy across ALS genotypes

Genotype n = With FTD Sex Age (Years) PMD (Hours) Fixation (Weeks)
M F Range Mean Std. Dev. Range Mean Std. Dev. Range Mean Std. Dev.
Control 17 0 10 7 36–95 62.5 14.0 18–73 42.5 16.0 0.2–32 7.1 9.2
Sporadic 39 7 21 18 44–90 65.5 11.7 24–120 47.7 22.5 0.2–28 5.9 8.5
C9ORF72a 18 5 11 7 42–76 60.6 9.4 4–96 47.5 30.5 0.2–17 7.5 4.8
SOD1b 11 0 3 8 34–78 55.9 14.7 5–96 39.0 31.9 3–20 11.8 5.8
FUSc 9 0 4 5 18–64 37.9 15.2 19–72 47.0 19.5 2–45 12.6 13.7
CHMP2Bd 2 0 1 1 51–69 60.0 12.7 12–22 17.0 7.1 3–4.5 3.8 1.1
HNRNPA1e 1 0 0 1 62 62.0 48 48.0 12.0 12.0
OPTNf 1 0 1 0 54 54.0 72 72.0 12.0 12.0
TARDBPg 1 0 1 0 57 57.0 48 48.0 9.0 9.0
  1. aC9ORF72 – Chromosome 9 open reading frame 72; bSOD1 – Superoxide dismutase 1; cFUS – Fused-in-sarcoma; dCHMP2B – Charged multivesicular body protein 2B; eHNRNPA1 – Heterogeneous nuclear ribonucleoprotein A1; fOPTN – Optineurin; gTARDBP – TAR DNA-binding protein. PMD = post-mortem delay
\